At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Oseltamivirdrug
Likely dose
Oseltamivir 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oseltamivir and Oseltamivir Carboxylate Pharmacokinetics in Obese Adults
In Brief
A Phase 2 clinical trial evaluating Oseltamivir for Obesity. Completed, enrolled 21 participants across 1 site.
Detailed Summary
One in three Americans are obese. Obese subjects may or may not need higher doses of the anti-flu drug known as Tamiflu (oseltamivir). The current study is being done to see if the FDA approved dose of oseltamivir will achieve similar concentrations in obese healthy volunteers compared to that previously shown in non-obese volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsHoffmann-La Roche
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedAug 2010
Primary CompletionSep 2010
Study CompletionDec 2010
TodayJul 2026
First PostedAug 11, 2010
Enrollment StartJul 1, 2010
Primary CompletionSep 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.9 years ago
Interventions
Oseltamivirdrug
Capsule, 75 mg by mouth for 9 doses